<DOC>
	<DOCNO>NCT01128335</DOCNO>
	<brief_summary>This study ass safety efficacy different dos sotrastaurin combine tacrolimus prevention acute rejection de novo liver transplantation .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability , Pharmacokinetics Sotrastaurin-tacrolimus vs. Mycophenolic Acid-tacrolimus de Novo Liver Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion criterion : Recipients race , 18 year old Recipients primary de novo orthotopic liver transplant decease donor Recipients kidney cold ischemia time &lt; 30 hour HCVnegative recipient Exclusion criterion : Prior organ/cellular transplant multiple organ transplant MELDscore &gt; 35 HCC &gt; Milan criterion Donor age &lt; 12 year Cold ischemia &gt; 15 hour Patients treat drug strong inducer inhibitor cytochrome P450 3A4 ( CYP3A4 ) drug QTprolonging property Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Liver transplantation</keyword>
	<keyword>HCV-negative recipient</keyword>
	<keyword>decease donor</keyword>
	<keyword>sotrastaurin</keyword>
	<keyword>oran transplantation</keyword>
	<keyword>tacrolimus</keyword>
</DOC>